Researcher profile

Pavel Mozgunov

Pavel Mozgunov contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 21 - EmergingVerification L1Unclaimed author
6works
0followers
7topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

6 published item(s)

preprint2026arXiv

A response-adaptive multi-arm design for continuous endpoints based on a weighted information measure

Multi-arm trials are gaining interest in practice given the statistical and logistical advantages they can offer. The standard approach uses a fixed allocation ratio, but there is a call for making it adaptive and skewing the allocation of patients towards better-performing arms. However, it is well-known that these approaches might suffer from lower statistical power. We present a response-adaptive design for continuous endpoints which explicitly allows to control the trade-off between the number of patients allocated to the "optimal" arm and the statistical power. Such a balance is achieved through the calibration of a tuning parameter, and we explore robust procedures to select it. The proposed criterion is based on a context-dependent information measure which gives greater weight to treatment arms with characteristics close to a pre-specified clinical target. We establish conditions under which the procedure consistently selects the target arm and derive the corresponding limiting allocation ratios. We also introduce a simulation-based hypothesis testing procedure which focuses on selecting the target arm and discuss strategies to effectively control the type-I error rate. The practical implementation of the proposed criterion and its potential advantage over currently used alternatives are illustrated in the context of early Phase IIa proof-of-concept oncology trials.

preprint2022arXiv

Bayesian sample size determination in basket trials borrowing information between subsets

Basket trials are increasingly used for the simultaneous evaluation of a new treatment in various patient subgroups under one overarching protocol. We propose a Bayesian approach to sample size determination in basket trials that permit borrowing of information between commensurate subsets. Specifically, we consider a randomised basket trial design where patients are randomly assigned to the new treatment or a control within each trial subset (`subtrial' for short). Closed-form sample size formulae are derived to ensure each subtrial has a specified chance of correctly deciding whether the new treatment is superior to or not better than the control by some clinically relevant difference. Given pre-specified levels of pairwise (in)commensurability, the subtrial sample sizes are solved simultaneously. The proposed Bayesian approach resembles the frequentist formulation of the problem in yielding comparable sample sizes for circumstances of no borrowing. When borrowing is enabled between commensurate subtrials, a considerably smaller trial sample size is required compared to the widely implemented approach of no borrowing. We illustrate the use of our sample size formulae with two examples based on real basket trials. A comprehensive simulation study further shows that the proposed methodology can maintain the true positive and false positive rates at desired levels.

preprint2020arXiv

Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs

Adaptive designs for clinical trials permit alterations to a study in response to accumulating data in order to make trials more flexible, ethical and efficient. These benefits are achieved while preserving the integrity and validity of the trial, through the pre-specification and proper adjustment for the possible alterations during the course of the trial. Despite much research in the statistical literature highlighting the potential advantages of adaptive designs over traditional fixed designs, the uptake of such methods in clinical research has been slow. One major reason for this is that different adaptations to trial designs, as well as their advantages and limitations, remain unfamiliar to large parts of the clinical community. The aim of this paper is to clarify where adaptive designs can be used to address specific questions of scientific interest; we introduce the main features of adaptive designs and commonly used terminology, highlighting their utility and pitfalls, and illustrate their use through case studies of adaptive trials ranging from early-phase dose escalation to confirmatory Phase III studies.

preprint2020arXiv

Efficient adaptive designs for clinical trials of interventions for COVID-19

The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible. This presents a number of challenges associated with considerable uncertainty over the natural history of the disease and the number and characteristics of patients affected, and the emergence of new potential therapies. These challenges make adaptive designs for clinical trials a particularly attractive option. Such designs allow a trial to be modified on the basis of interim analysis data or stopped as soon as sufficiently strong evidence has been observed to answer the research question, without compromising the trial's scientific validity or integrity. In this paper we describe some of the adaptive design approaches that are available and discuss particular issues and challenges associated with their use in the pandemic setting. Our discussion is illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.

preprint2015arXiv

Asymptotic behaviour of weighted differential entropies in a Bayesian problem

We consider a Bayesian problem of estimating of probability of success in a series of conditionally independent trials with binary outcomes. We study the asymptotic behaviour of differential entropy for posterior probability density function conditional on $x$ successes after $n$ conditionally independent trials, when $n \to \infty$. It is shown that after an appropriate normalization in cases $x \sim n$ and $x$ $\sim n^β$ ($0<β<1$) limiting distribution is Gaussian and the differential entropy of standardized RV converges to differential entropy of standard Gaussian random variable. When $x$ or $n-x$ is a constant the limiting distribution in not Gaussian, but still the asymptotic of differential entropy can be found explicitly. Then suppose that one is interested to know whether the coin is fair or not and for large $n$ is interested in the true frequency. To do so the concept of weighted differential entropy introduced in \cite{Belis1968} is used when the frequency $γ$ is necessary to emphasize. It was found that the weight in suggested form does not change the asymptotic form of Shannon, Renyi, Tsallis and Fisher entropies, but change the constants. The main term in weighted Fisher Information is changed by some constant which depend on distance between the true frequency and the value we want to emphasize. In third part we derived the weighted versions of Rao-Cramér, Bhattacharyya and Kullback inequalities. This result is applied to the Bayesian problem described above. The asymptotic forms of these inequalities are obtained for a particular class of weight functions.

preprint2015arXiv

Limits of Kalman Filter application in heavy tailed problems

In this paper we consider the behavior of Kalman Filter state estimates in the case of distribution with heavy tails .The simulated linear state space models with Gaussian measurement noises were used. Gaussian noises in state equation are replaced by components with alpha-stable distribution with di erent parameters alpha and beta. We consider the case when &#34;all parameters are known&#34; and two methods of parameters estimation are compared: the maximum likelihood estimator (MLE) and the expectation- maximization algorithm (EM). It was shown that in cases of large deviation from Gaussian distribution the total error of states estimation rises dramatically. We conjecture that it can be explained by underestimation of the state equation noises covariance matrix that can be taken into account through the EM parameters estimation and ignored in the case of ML estimation.